We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

加利福尼亚州卡尔斯巴德 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)已确认计划于2025年上半年启动ION582的第三期研究,这是一种潜在的安格尔曼综合征 (AS)治疗方法。这一决定是在与美国食品和药物管理局 (FDA)成功会晤并就最终研究设计达成一致后做出的。

加利福尼亚州卡尔斯巴德 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)已收到美国食品和药物管理局(FDA)的确认,其新药申请(NDA)donidalorsen正在审核中。Donidalorsen是一种研究中的RNA靶向药物,旨在预防12岁及以上患者的遗传性血管性水肿(HAE)发作。 FDA已将处方药用户费法案(PDUFA)行动日期定为2025年8月21日。如 ...

Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $55.00. Michael Ulz has given his ...

The sequestrants market is projected to surpass USD 754 million in 2024 and to reach USD 1,289 million in 2034. Demand for Sequestrants has a CAGR of 11.3% throughout the forecast period (2024 to 2034 ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price ...